Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. (ALNY) Healthcare & Pipeline Overview

Alnylam Pharmaceuticals, Inc. pioneers RNAi therapeutics, developing and commercializing innovative medicines for genetic and other diseases. With marketed products like ONPATTRO, GIVLAARI, and OXLUMO, Alnylam targets significant unmet medical needs, positioning itself as a leader in the rapidly evolving biotechnology sector and personalized medicine.

What Is the Investment Thesis for ALNY?

Alnylam Pharmaceuticals, Inc. presents a notable research candidate driven by its leadership in RNAi therapeutics and a robust pipeline of innovative medicines. With a market capitalization of $41.79B and a profit margin of 13.5%, Alnylam demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of ONPATTRO, GIVLAARI, and OXLUMO, as well as the advancement of pipeline candidates like Zilebesiran for hypertension and ALN-HSD for NASH. Upcoming catalysts include the potential approval and launch of vutrisiran for ATTR amyloidosis, which is currently in Phase 3 clinical trials. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. Alnylam's high P/E ratio of 69.5 reflects investor expectations for future growth, but also indicates a potential vulnerability to market corrections.

Based on FMP financials and quantitative analysis

ALNY Key Highlights

• Market capitalization of $41.79B, reflecting strong investor confidence in Alnylam's RNAi therapeutics platform.
• Profit margin of 13.5%, indicating efficient operations and successful commercialization of key products.
• Gross margin of 80.9%, demonstrating the high value and competitive pricing of Alnylam's innovative therapies.
• Beta of 0.38, suggesting lower volatility compared to the broader market, which may appeal to risk-averse investors.
• Strategic collaborations with Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme, enhancing research and development capabilities and market reach.

Who Are ALNY's Competitors?

ALNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALNY's Key Strengths?

• Pioneering RNAi technology platform.
• Diverse pipeline of RNAi therapeutics.
• Established partnerships with major pharmaceutical companies.
• Approved and marketed products with proven efficacy.

What Are ALNY's Weaknesses?

• High research and development costs.
• Reliance on regulatory approvals.
• Competition from established pharmaceutical companies.
• Potential for clinical trial failures.

What Could Drive ALNY Stock Higher?

• Potential FDA approval and launch of vutrisiran for the treatment of ATTR amyloidosis.
• Continued commercial expansion of ONPATTRO, GIVLAARI, and OXLUMO in existing and new markets.
• Progress in clinical trials for Zilebesiran for hypertension and ALN-HSD for NASH.
• Data readouts from ongoing clinical trials for pipeline candidates targeting various diseases.

What Are the Key Risks for ALNY?

• Rich valuation — a P/E of 69.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Clinical trial failures for pipeline candidates.
• Regulatory delays or rejections for new drug applications.
• Competition from other pharmaceutical companies developing therapies for similar diseases.
• Patent expirations and potential biosimilar competition for marketed products.
• Changes in healthcare regulations affecting pricing and reimbursement.

What Are the Growth Opportunities for ALNY?

• Expansion of RNAi Therapeutics into New Therapeutic Areas: Alnylam has the opportunity to expand its RNAi therapeutics platform into new therapeutic areas, such as oncology and immunology. The market for oncology drugs is projected to reach $286 billion by 2030, offering a significant growth opportunity for Alnylam. By leveraging its expertise in RNAi technology, Alnylam can develop targeted therapies for various types of cancer and immune-related disorders, addressing unmet medical needs and driving revenue growth.
• Commercialization of Vutrisiran for ATTR Amyloidosis: Vutrisiran, currently in Phase 3 clinical trials, represents a significant growth opportunity for Alnylam. ATTR amyloidosis is a rare and progressive disease with limited treatment options, creating a substantial market for effective therapies. If approved, vutrisiran could generate significant revenue for Alnylam, further solidifying its position as a leader in RNAi therapeutics. The global market for ATTR amyloidosis treatment is expected to reach $2.5 billion by 2028.
• Advancement of Zilebesiran for Hypertension: Zilebesiran, an RNAi therapeutic targeting hypertension, has the potential to address a large and underserved market. Hypertension affects millions of people worldwide and is a major risk factor for cardiovascular disease. By developing an effective and convenient treatment for hypertension, Alnylam can capture a significant share of the market and improve patient outcomes. The global market for hypertension drugs is projected to reach $30 billion by 2027.
• Strategic Collaborations and Partnerships: Alnylam can continue to drive growth through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These collaborations can provide access to new technologies, expand research and development capabilities, and accelerate the commercialization of RNAi therapeutics. Alnylam's existing collaborations with Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme demonstrate the value of this approach.
• Geographic Expansion into Emerging Markets: Alnylam has the opportunity to expand its geographic reach into emerging markets, such as China and India. These markets have a large and growing population with increasing healthcare needs. By establishing a presence in these markets, Alnylam can tap into new sources of revenue and expand the global reach of its RNAi therapeutics. The pharmaceutical market in China is projected to reach $450 billion by 2030.

What Opportunities Does ALNY Have?

• Expansion into new therapeutic areas.
• Commercialization of pipeline candidates.
• Geographic expansion into emerging markets.
• Further development of RNAi technology.

What Threats Does ALNY Face?

• Patent expirations.
• Biosimilar competition.
• Changes in healthcare regulations.
• Economic downturns affecting healthcare spending.

What Are ALNY's Competitive Advantages?

• Proprietary RNAi Technology: Alnylam possesses a leading position in RNAi technology, creating a barrier to entry for competitors.
• Patent Protection: Strong patent portfolio protects key products and technologies, providing market exclusivity.
• Clinical Data: Extensive clinical data supports the efficacy and safety of Alnylam's therapies, building trust with healthcare providers.
• Strategic Partnerships: Collaborations with major pharmaceutical companies enhance research, development, and commercialization efforts.

What Does ALNY Do?

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company at the forefront of RNA interference (RNAi) therapeutics. The company was established with the vision of harnessing the power of RNAi to develop a new class of medicines for patients with limited or inadequate treatment options. RNAi is a natural cellular process that silences specific genes, offering a unique approach to treating diseases at their source. Alnylam's marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). The company's pipeline includes therapies targeting genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Alnylam has established strategic collaborations with companies like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme to expand its research and development efforts and commercialize its RNAi therapeutics. These collaborations are crucial for addressing therapeutic targets in the eye and CNS, and for advancing RNAi therapeutics globally. Alnylam continues to focus on advancing its pipeline and expanding the reach of RNAi therapeutics to address unmet medical needs.

What Products and Services Does ALNY Offer?

• Discovers novel therapeutics based on ribonucleic acid interference (RNAi).
• Develops RNAi therapeutics for genetic medicines.
• Creates RNAi therapeutics for cardio-metabolic diseases.
• Develops RNAi therapeutics for hepatic infectious diseases.
• Focuses on RNAi therapeutics for central nervous system (CNS)/ocular diseases.
• Markets ONPATTRO for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.
• Markets GIVLAARI for the treatment of acute hepatic porphyria (AHP).
• Markets OXLUMO for the treatment of primary hyperoxaluria type 1 (PH1).

How Does ALNY Make Money?

• Develops and patents RNAi-based therapeutics.
• Conducts clinical trials to demonstrate safety and efficacy.
• Obtains regulatory approvals from agencies like the FDA.
• Commercializes and markets approved drugs globally.
• Collaborates with other companies for research and development.

What Industry Does ALNY Operate In?

Alnylam Pharmaceuticals, Inc. operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The global biotechnology market is projected to reach $3.87 trillion by 2030, growing at a CAGR of 12.3% from 2024. Alnylam's focus on RNAi therapeutics positions it at the forefront of personalized medicine, offering a unique approach to treating diseases at their genetic source. Competitors include companies like Regeneron Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., which are also developing innovative therapies for genetic and other diseases. Alnylam's success depends on its ability to continue innovating, securing regulatory approvals, and effectively commercializing its products.

Who Are ALNY's Key Customers?

• Patients with hereditary transthyretin-mediated amyloidosis (hATTR).
• Patients with acute hepatic porphyria (AHP).
• Patients with primary hyperoxaluria type 1 (PH1).
• Healthcare providers who prescribe Alnylam's medications.
• Hospitals and clinics that administer Alnylam's therapies.

Company Profile

Alnylam Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Yvonne L. Greenstreet. ALNY has traded publicly since 2004.

ROE 98%Key Financial Metrics

Return on equity for Alnylam Pharmaceuticals, Inc. stands at 98.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.3%, showing how much profit it generates from its asset base. ALNY trades at a trailing price-to-earnings ratio of 69.53, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.4%, the inverse of the P/E and a quick read on earnings relative to price.

ALNY Valuation & Market Position

With a $41.79B market cap, Alnylam Pharmaceuticals, Inc. sits in the large-cap segment of the market. Relative to its peer group, ALNY's quantitative score of 95/100 is above the peer average of 80/100.

Quarterly Financial Performance: Alnylam Pharmaceuticals, Inc.

Revenue for Alnylam Pharmaceuticals, Inc. came in at $1.17B during Q1 2026, a 6.4% improvement versus the preceding quarter. The company recorded net income of $206.0M, with diluted EPS of $1.51. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ALNY averaged $1.05 in diluted EPS.

F-Score 7/9Financial Health

Alnylam Pharmaceuticals, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 6.47 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Alnylam Pharmaceuticals, Inc. revenue of about $5.60B for fiscal 2026, with EPS near $7.44. The estimate reflects 20 contributing analysts.

ALNY Financials

ALNY Latest News

ALNY Analyst Consensus

ALNY MoonshotScore

Common Questions About ALNY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources